Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds

Enveric Biosciences ENVB announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI). 

The compounds span seven distinct molecule classes totaling at least 57 unique product opportunities, all protected by Enveric's expansive intellectual property portfolio.

The compounds also represent potential out-licensing opportunities and non-dilutive revenue streams for the company. 

The new molecule classes broaden and deepen Enveric's library of assets targeting difficult-to-address mental health disorders, adding to its lead candidate EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002 (formerly EB-373), a next-generation synthetic prodrug of the active metabolite, psilocin.

The compounds include:

• Novel Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors (SNDRI), also known as triple reuptake inhibitors, SNDRIs are an emerging class of medications designed to treat severe depression and anxiety disorders.
  • Enveric SNDRI compounds show strong binding to serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT).
  • Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone. 
•  Non-selective Serotonin Reuptake Inhibitor (NSRI)
  • Certain Enveric's NSRIs demonstrate additional binding to various serotonin and dopamine family receptors, with binding profiles similar to the antidepressant Vortioxetine and the atypical antipsychotic Aripiprazole. 
• Novel MDMA Derivatives (EMD) Series 
  • Some of the resulting receptor binding profiles are similar to the anxiolytic Buspirone, the antiepileptic Fenfluramine, the ADHD drug Guanfacine, and the atypical antipsychotic Aripiprazole.
• Bifunctional Psilocin Prodrugs (BPP) are readily absorbed, detectable in plasma, and converted to therapeutically relevant levels of plasma psilocin, with demonstrated lower Head Twitch Response (HTR) relative to psilocybin in mice; HTR is reported in the literature to be a predictive indicator for hallucination in humans.
  • Each BPP parent prodrug demonstrates its unique binding profile to serotonin 5-HT1A receptor, 5-HT1B receptor, and SERT, with similarities to anxiolytics Buspirone, antidepressant/anxiolytic Flesinoxan, and the antidepressant Paroxetine.
• Novel Psilocin Prodrug (NPP) Series 
  • NPPs are designed to be metabolized to release therapeutic levels of systemic psilocin at varying rates, providing treatment regimen optionality.
• Melatonin-Receptor Agonist (MRA) Series
  • Melatonin, a natural indolamine, is essential for regulating circadian rhythm in mammals and is often used to treat various sleep disorders.
  • Enveric MRA compounds demonstrate strong binding to the MT1 Melatonin receptor, with some being highly selective for MT1 while others demonstrate expanded target binding profiles similar to the antidepressants Agomelatine, Vortioxetine, Imipramine, and Trazodone. 
• Neuroplastogenic Antidepressant (NAD-01)
  • Designed to induce neuroplasticity and promote long-term therapeutic benefit in patients suffering from severe depressive mood disorders.

Price Action: ENVB shares closed at $0.87 on Tuesday.